The findings presented at a conference in Chicago found a slightly lower risk of obesity-related cancers when adults with ...

The percentage of adult patients with a diagnosis of overweight or obesity increased from 10.4% in 2019 to 15.7% in 2024.

On May 29, analysts at Stifel raised their price target for Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) from $78 to $94 while ...

The report also underscored the importance of maintaining muscle mass and bone density while losing weight. Since weight loss ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

As a result, a market for cheaper, off-brand versions of their active ingredients — semaglutide and tirzepatide — has ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find ...

BioAge Labs, Inc. (NASDAQ:BIOA), a clinical-stage biotech innovator, announced today the completion of IND-enabling studies ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Awareness Month, which seeks to raise recognition and push for research of this rare genomic imprinting disorder. PWS is estimated to affect about one in 20 000 individuals1 yet, until now, people ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

The FDA has approved the first at-home cervical cancer test and weight loss drugs could reduce obesity related cancers.